These results collectively suggested that both FoxP3+ and IL-17+ T cells are important components of TILs in breast cancer patients, and that the increase and activation of FoxP3+ Treg cells is an important strategy for tumor escaping from anti-tumor immunity during tumor development. Here, IL17A is linked to neoplasm.